[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07489495":3,"trial-entities:NCT07489495":807,"trial-summary:NCT07489495":811},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":49,"secondary_outcomes":58,"sex":98,"minimum_age":99,"maximum_age":17,"healthy_volunteers":100,"eligibility_criteria":101,"std_ages":119,"locations":122,"central_contacts":793,"overall_officials":798,"references":802,"see_also_links":803},"NCT07489495","6482-034","A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034\u002FLS-034\u002FMK-6482-034)","A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1\u002FL1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)","RECRUITING","2030-11-27","2026-07","2026-07-27","2026-04-09","Merck Sharp & Dohme LLC","INDUSTRY",true,"Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).\n\nA standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.\n\nThe goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.",null,[19],"Carcinoma, Renal Cell",[],"INTERVENTIONAL","TREATMENT",[24],"PHASE3",{"count":26,"type":27},758,"ESTIMATED",[29,40,45],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":36},"DRUG","Belzutifan","Tablet for oral administration.",[34,35],"Belzutifan + Placebo","Belzutifan + Zanzalintinib",[37,38,39],"MK-6482","PT2977","WELIREG",{"type":30,"name":41,"description":32,"armGroupLabels":42,"otherNames":43},"Zanzalintinib",[35],[44],"XL092",{"type":30,"name":46,"description":47,"armGroupLabels":48},"Placebo","Zanzalintinib-matching placebo tablet for oral administration.",[34],[50,54],{"measure":51,"description":52,"timeFrame":53},"Progression-free Survival (PFS)","PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first.","Up to approximately 30 months",{"measure":55,"description":56,"timeFrame":57},"Overall Survival (OS)","OS is defined as the time from randomization to death due to any cause.","Up to approximately 50 months",[59,62,65,69,73,77,80,83,86,89,92,95],{"measure":60,"description":61,"timeFrame":53},"Objective Response Rate (ORR)","ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.",{"measure":63,"description":64,"timeFrame":53},"Duration of Response (DOR)","DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.",{"measure":66,"description":67,"timeFrame":68},"Number of Participants Who Experience One or More Adverse Events (AEs)","An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported.","Up to approximately 25 months",{"measure":70,"description":71,"timeFrame":72},"Number of Participants who Discontinue Study Treatment Due to an AE","An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.","Up to approximately 24 months",{"measure":74,"description":75,"timeFrame":76},"Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score","EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; \"How would you rate your overall health during the past week?\") and QoL (\"How would you rate your overall quality of life during the past week?\") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented.","Baseline and up to approximately 25 months",{"measure":78,"description":79,"timeFrame":76},"Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score","EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented.",{"measure":81,"description":82,"timeFrame":76},"Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score","The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported.",{"measure":84,"description":85,"timeFrame":76},"Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score","The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome.",{"measure":87,"description":88,"timeFrame":68},"Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score","EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS (\"How would you rate your overall health during the past week?\") and QoL (\"How would you rate your overall QoL during the past week?\") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.",{"measure":90,"description":91,"timeFrame":68},"TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score","EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.",{"measure":93,"description":94,"timeFrame":68},"TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score","EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome.",{"measure":96,"description":97,"timeFrame":68},"TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score","TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome.","ALL","18 Years",false,{"inclusion":102,"exclusion":106,"raw_text":118},[103,104,105],"Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)","Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)","Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1\u002FProgrammed Cell Death 1 Ligand 1 therapy",[107,108,109,110,111,112,113,114,115,116,117],"Has any of the following: a pulse oximeter reading \\\u003C92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen","Has clinically significant cardiovascular disease within 12 months from first dose of study intervention","Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization","Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram","Has had major surgery within 8 weeks before randomization","Has current pneumonitis\u002Finterstitial lung disease","Has a history of human immunodeficiency virus infection","Has Hepatitis B or Hepatitis C virus infection","Has a known additional malignancy that is progressing or has required active treatment within the past 3 years","Has a history of solid organ transplant","Has not adequately recovered from major surgery or has ongoing surgical complications","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)\n* Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1\u002FProgrammed Cell Death 1 Ligand 1 therapy\n\nExclusion Criteria:\n\nFor exclusion criteria: The main exclusion criteria include but are not limited to the following:\n\n* Has any of the following: a pulse oximeter reading \\\u003C92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention\n* Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization\n* Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram\n* Has had major surgery within 8 weeks before randomization\n* Has current pneumonitis\u002Finterstitial lung disease\n* Has a history of human immunodeficiency virus infection\n* Has Hepatitis B or Hepatitis C virus infection\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has a history of solid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",[120,121],"ADULT","OLDER_ADULT",[123,137,148,157,164,174,185,196,203,209,219,229,236,248,259,270,281,293,304,314,324,336,347,359,370,381,392,403,410,422,434,441,448,459,469,479,489,501,512,522,532,542,549,561,572,583,595,606,617,627,638,649,656,663,675,686,697,706,716,723,733,742,752,761,771,781],{"facility":124,"status":8,"city":125,"state":126,"zip":127,"country":128,"contacts":129,"geoPoint":134},"Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)","Marietta","Georgia","30060","United States",[130],{"name":131,"role":132,"phone":133},"Study Coordinator","CONTACT","770-281-5124",{"lat":135,"lon":136},33.9526,-84.54993,{"facility":138,"status":8,"city":139,"state":140,"zip":141,"country":128,"contacts":142,"geoPoint":145},"The West Clinic, P.C. ( Site 0115)","Germantown","Tennessee","38138",[143],{"name":131,"role":132,"phone":144},"901-683-0055",{"lat":146,"lon":147},35.08676,-89.81009,{"facility":149,"status":8,"city":150,"state":151,"zip":152,"country":153,"contacts":154},"Centro Oncologico Korben ( Site 0254)","CABA","Buenos Aires","C1426AHB","Argentina",[155],{"name":131,"role":132,"phone":156},"+541159507952",{"facility":158,"status":8,"city":159,"state":151,"zip":160,"country":153,"contacts":161},"Hospital Italiano de Buenos Aires ( Site 0253)","Ciudad de Buenos Aires","1181",[162],{"name":131,"role":132,"phone":163},"+541149590200",{"facility":165,"status":8,"city":166,"state":151,"zip":167,"country":153,"contacts":168,"geoPoint":171},"Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)","Mar del Plata","B7600FZO",[169],{"name":131,"role":132,"phone":170},"+542234963224",{"lat":172,"lon":173},-38.00042,-57.5562,{"facility":175,"status":8,"city":176,"state":177,"zip":178,"country":153,"contacts":179,"geoPoint":182},"Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)","Río Cuarto","Córdoba Province","X5800ALB",[180],{"name":131,"role":132,"phone":181},"+543584620273",{"lat":183,"lon":184},-33.13044,-64.35272,{"facility":186,"status":8,"city":187,"state":188,"zip":189,"country":153,"contacts":190,"geoPoint":193},"Sanatorio Parque ( Site 0251)","Rosario","Santa Fe Province","S2000DSV",[191],{"name":131,"role":132,"phone":192},"+5493416955611",{"lat":194,"lon":195},-32.94682,-60.63932,{"facility":197,"status":8,"city":187,"state":188,"zip":198,"country":153,"contacts":199,"geoPoint":202},"Instituto de Oncología de Rosario ( Site 0257)","S2000KZE",[200],{"name":131,"role":132,"phone":201},"+543414484830",{"lat":194,"lon":195},{"facility":204,"status":8,"city":150,"zip":205,"country":153,"contacts":206},"Instituto Alexander Fleming ( Site 0252)","C1426ANZ",[207],{"name":131,"role":132,"phone":208},"+541132218900",{"facility":210,"status":8,"city":211,"zip":212,"country":153,"contacts":213,"geoPoint":216},"Centro Oncológico Riojano Integral ( Site 0256)","La Rioja","X5004BAL",[214],{"name":131,"role":132,"phone":215},"+543804436443X108",{"lat":217,"lon":218},-29.41328,-66.85637,{"facility":220,"status":8,"city":221,"zip":222,"country":153,"contacts":223,"geoPoint":226},"COE (Centro Oncológico de Excelencia) ( Site 0259)","San Juan","J5402BGA",[224],{"name":131,"role":132,"phone":225},"+54 2644229585",{"lat":227,"lon":228},-31.53726,-68.52568,{"facility":230,"status":231,"city":232,"state":233,"zip":234,"country":235},"Macquarie University ( Site 2700)","SUSPENDED","Macquarie University","New South Wales","2109","Australia",{"facility":237,"status":8,"city":238,"state":239,"zip":240,"country":241,"contacts":242,"geoPoint":245},"CEDOES ( Site 0303)","Vitória","Espírito Santo","29055-450","Brazil",[243],{"name":131,"role":132,"phone":244},"+552721250202",{"lat":246,"lon":247},-20.31944,-40.33778,{"facility":249,"status":8,"city":250,"state":251,"zip":252,"country":241,"contacts":253,"geoPoint":256},"Instituto do Câncer e Transplante de Curitiba ( Site 0300)","Curitiba","Paraná","80510-130",[254],{"name":131,"role":132,"phone":255},"+55 41 99205-7755",{"lat":257,"lon":258},-25.42778,-49.27306,{"facility":260,"status":8,"city":261,"state":262,"zip":263,"country":241,"contacts":264,"geoPoint":267},"Liga Norte Riograndense Contra o Câncer ( Site 0307)","Natal","Rio Grande do Norte","59062-000",[265],{"name":131,"role":132,"phone":266},"+55 84 4009-5595",{"lat":268,"lon":269},-5.795,-35.20944,{"facility":271,"status":8,"city":272,"state":273,"zip":274,"country":241,"contacts":275,"geoPoint":278},"Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)","São José do Rio Preto","São Paulo","15090-000",[276],{"name":131,"role":132,"phone":277},"+55 17 3201-5054",{"lat":279,"lon":280},-20.81972,-49.37944,{"facility":282,"status":8,"city":283,"state":284,"zip":285,"country":286,"contacts":287,"geoPoint":290},"Masarykuv onkologicky ustav ( Site 0903)","Brno","Brno-mesto","656 53","Czechia",[288],{"name":131,"role":132,"phone":289},"+420543132216",{"lat":291,"lon":292},49.19522,16.60796,{"facility":294,"status":8,"city":295,"state":296,"zip":297,"country":286,"contacts":298,"geoPoint":301},"Fakultni nemocnice Ostrava ( Site 0904)","Ostrava","Ostrava Mesto","708 52",[299],{"name":131,"role":132,"phone":300},"+420597374322",{"lat":302,"lon":303},49.83465,18.28204,{"facility":305,"status":8,"city":306,"zip":307,"country":286,"contacts":308,"geoPoint":311},"Fakultni nemocnice Hradec Kralove ( Site 0902)","Hradec Králové","500 05",[309],{"name":131,"role":132,"phone":310},"+420727854666",{"lat":312,"lon":313},50.20923,15.83277,{"facility":315,"status":8,"city":316,"zip":317,"country":286,"contacts":318,"geoPoint":321},"Fakultni nemocnice v Motole ( Site 0900)","Prague","150 06",[319],{"name":131,"role":132,"phone":320},"+420734236410",{"lat":322,"lon":323},50.08804,14.42076,{"facility":325,"status":8,"city":326,"state":327,"zip":328,"country":329,"contacts":330,"geoPoint":333},"Herlev Hospital ( Site 1002)","Herlev","Capital Region","2730","Denmark",[331],{"name":131,"role":132,"phone":332},"00 45 38689191",{"lat":334,"lon":335},55.72366,12.43998,{"facility":337,"status":8,"city":338,"state":339,"zip":340,"country":329,"contacts":341,"geoPoint":344},"Aarhus Universitetshospital, Skejby ( Site 1001)","Aarhus","Central Jutland","8200",[342],{"name":131,"role":132,"phone":343},"+4591167472",{"lat":345,"lon":346},56.15674,10.21076,{"facility":348,"status":8,"city":349,"state":350,"zip":351,"country":352,"contacts":353,"geoPoint":356},"Centre Antoine Lacassagne ( Site 1209)","Nice","Alpes-Maritimes","06189","France",[354],{"name":131,"role":132,"phone":355},"+33492031538",{"lat":357,"lon":358},43.70313,7.26608,{"facility":360,"status":8,"city":361,"state":362,"zip":363,"country":352,"contacts":364,"geoPoint":367},"Hopital Europeen Marseille ( Site 1216)","Marseille","Bouches-du-Rhone","13003",[365],{"name":131,"role":132,"phone":366},"+33413427427",{"lat":368,"lon":369},43.29695,5.38107,{"facility":371,"status":8,"city":372,"state":373,"zip":374,"country":352,"contacts":375,"geoPoint":378},"LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)","Toulouse","Haute-Garonne","31059",[376],{"name":131,"role":132,"phone":377},"+33531155050",{"lat":379,"lon":380},43.60426,1.44367,{"facility":382,"status":8,"city":383,"state":384,"zip":385,"country":352,"contacts":386,"geoPoint":389},"CHU Angers ( Site 1204)","Angers","Maine-et-Loire","49933",[387],{"name":131,"role":132,"phone":388},"+33241354694",{"lat":390,"lon":391},47.47156,-0.55202,{"facility":393,"status":8,"city":394,"state":395,"zip":396,"country":352,"contacts":397,"geoPoint":400},"Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)","Le Mans","Pays de la Loire Region","72000",[398],{"name":131,"role":132,"phone":399},"+33 243297908",{"lat":401,"lon":402},48.0021,0.20251,{"facility":404,"status":8,"city":405,"state":395,"zip":406,"country":352,"contacts":407},"CHU de Saint-Etienne ( Site 1202)","Saint Priest En Jarez","42271",[408],{"name":131,"role":132,"phone":409},"+33477917082",{"facility":411,"status":8,"city":412,"state":413,"zip":414,"country":415,"contacts":416,"geoPoint":419},"Universitätsklinikum Jena ( Site 1313)","Jena","Thuringia","07747","Germany",[417],{"name":131,"role":132,"phone":418},"+4936419329947",{"lat":420,"lon":421},50.92878,11.5899,{"facility":423,"status":8,"city":424,"state":425,"zip":426,"country":427,"contacts":428,"geoPoint":431},"Alexandra General Hospital of Athens ( Site 1400)","Athens","Attica","115 28","Greece",[429],{"name":131,"role":132,"phone":430},"+302132162543",{"lat":432,"lon":433},37.98376,23.72784,{"facility":435,"status":8,"city":424,"state":425,"zip":436,"country":427,"contacts":437,"geoPoint":440},"ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)","124 62",[438],{"name":131,"role":132,"phone":439},"+302105832549",{"lat":432,"lon":433},{"facility":442,"status":8,"city":424,"state":425,"zip":443,"country":427,"contacts":444,"geoPoint":447},"Metropolitan Hospital ( Site 1402)","185 47",[445],{"name":131,"role":132,"phone":446},"+302104809667",{"lat":432,"lon":433},{"facility":449,"status":8,"city":450,"zip":451,"country":452,"contacts":453,"geoPoint":456},"Rambam Health Care Campus ( Site 1600)","Haifa","3109601","Israel",[454],{"name":131,"role":132,"phone":455},"+97247772688",{"lat":457,"lon":458},32.81303,34.99928,{"facility":460,"status":8,"city":461,"zip":462,"country":452,"contacts":463,"geoPoint":466},"Meir Medical Center. ( Site 1603)","Kfar Saba","4428164",[464],{"name":131,"role":132,"phone":465},"+97297472555",{"lat":467,"lon":468},32.175,34.90694,{"facility":470,"status":8,"city":471,"zip":472,"country":452,"contacts":473,"geoPoint":476},"Rabin Medical Center ( Site 1602)","Petah Tikva","4941492",[474],{"name":131,"role":132,"phone":475},"97239378074",{"lat":477,"lon":478},32.08707,34.88747,{"facility":480,"status":8,"city":481,"zip":482,"country":452,"contacts":483,"geoPoint":486},"Sheba Medical Center ( Site 1601)","Ramat Gan","5265601",[484],{"name":131,"role":132,"phone":485},"97235303030",{"lat":487,"lon":488},32.08227,34.81065,{"facility":490,"status":8,"city":491,"state":492,"zip":493,"country":494,"contacts":495,"geoPoint":498},"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" ( Site 1809)","Meldola","Emilia-Romagna","47014","Italy",[496],{"name":131,"role":132,"phone":497},"+390543739100",{"lat":499,"lon":500},44.12775,12.0626,{"facility":502,"status":8,"city":503,"state":504,"zip":505,"country":494,"contacts":506,"geoPoint":509},"Azienda Ospedaliera Universitaria Careggi ( Site 1807)","Florence","Tuscany","50134",[507],{"name":131,"role":132,"phone":508},"+390557949648",{"lat":510,"lon":511},43.77925,11.24626,{"facility":513,"status":8,"city":514,"zip":515,"country":494,"contacts":516,"geoPoint":519},"Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)","Milan","20133",[517],{"name":131,"role":132,"phone":518},"02 2390 3028",{"lat":520,"lon":521},42.78235,12.59836,{"facility":523,"status":8,"city":524,"zip":525,"country":494,"contacts":526,"geoPoint":529},"AO Santa Maria della Misericordia ( Site 1805)","Perugia","06132",[527],{"name":131,"role":132,"phone":528},"+39 0755784188",{"lat":530,"lon":531},43.1122,12.38878,{"facility":533,"status":8,"city":534,"zip":535,"country":494,"contacts":536,"geoPoint":539},"Istituto Nazionale Tumori Regina Elena ( Site 1804)","Roma","00144",[537],{"name":131,"role":132,"phone":538},"+39 0652666919",{"lat":540,"lon":541},44.99364,11.10642,{"facility":543,"status":8,"city":534,"zip":544,"country":494,"contacts":545,"geoPoint":548},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)","00168",[546],{"name":131,"role":132,"phone":547},"00390630155202",{"lat":540,"lon":541},{"facility":550,"status":8,"city":551,"state":552,"zip":553,"country":554,"contacts":555,"geoPoint":558},"Maastricht UMC+ ( Site 1901)","Maastricht","Limburg","6229 HX","Netherlands",[556],{"name":131,"role":132,"phone":557},"+31433877025",{"lat":559,"lon":560},50.84833,5.68889,{"facility":562,"status":8,"city":563,"state":564,"zip":565,"country":554,"contacts":566,"geoPoint":569},"Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)","Amsterdam","North Holland","1066 CX",[567],{"name":131,"role":132,"phone":568},"+3120 512 9111",{"lat":570,"lon":571},52.37403,4.88969,{"facility":573,"status":8,"city":574,"state":575,"zip":576,"country":554,"contacts":577,"geoPoint":580},"Haga Ziekenhuis locatie Leyweg ( Site 1906)","The Hague","South Holland","2545 AA",[578],{"name":131,"role":132,"phone":579},"+3170 210 2143",{"lat":581,"lon":582},52.07667,4.29861,{"facility":584,"status":8,"city":585,"state":586,"zip":587,"country":588,"contacts":589,"geoPoint":592},"AIDPORT Sp. z o.o. ( Site 2118)","Skórzewo","Greater Poland Voivodeship","60-185","Poland",[590],{"name":131,"role":132,"phone":591},"+48570783100",{"lat":593,"lon":594},52.39085,16.78934,{"facility":596,"status":8,"city":597,"state":598,"zip":599,"country":588,"contacts":600,"geoPoint":603},"Pratia MCM Krakow ( Site 2115)","Krakow","Lesser Poland Voivodeship","30-727",[601],{"name":131,"role":132,"phone":602},"+48122958160",{"lat":604,"lon":605},50.06143,19.93658,{"facility":607,"status":8,"city":608,"state":609,"zip":610,"country":588,"contacts":611,"geoPoint":614},"Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2102)","Siedlce","Masovian Voivodeship","08-110",[612],{"name":131,"role":132,"phone":613},"+48256403300",{"lat":615,"lon":616},52.16772,22.29006,{"facility":618,"status":8,"city":619,"state":609,"zip":620,"country":588,"contacts":621,"geoPoint":624},"MTZ Clinical Research Powered by Pratia ( Site 2107)","Warsaw","02-172",[622],{"name":131,"role":132,"phone":623},"+48225725959",{"lat":625,"lon":626},52.22977,21.01178,{"facility":628,"status":8,"city":629,"state":630,"zip":631,"country":588,"contacts":632,"geoPoint":635},"Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)","Gliwice","Silesian Voivodeship","44-102",[633],{"name":131,"role":132,"phone":634},"+48322788237",{"lat":636,"lon":637},50.29761,18.67658,{"facility":639,"status":8,"city":640,"zip":641,"country":642,"contacts":643,"geoPoint":646},"Severance Hospital, Yonsei University Health System ( Site 2903)","Seoul","03722","South Korea",[644],{"name":131,"role":132,"phone":645},"+82-2-2228-8138",{"lat":647,"lon":648},37.566,126.9784,{"facility":650,"status":8,"city":640,"zip":651,"country":642,"contacts":652,"geoPoint":655},"Asan Medical Center ( Site 2901)","05505",[653],{"name":131,"role":132,"phone":654},"+82-2-3010-5977",{"lat":647,"lon":648},{"facility":657,"status":8,"city":640,"zip":658,"country":642,"contacts":659,"geoPoint":662},"Samsung Medical Center ( Site 2902)","06351",[660],{"name":131,"role":132,"phone":661},"+82-2-3410-1767",{"lat":647,"lon":648},{"facility":664,"status":8,"city":665,"state":666,"zip":667,"country":668,"contacts":669,"geoPoint":672},"Hospital Universitario Virgen del Rocio ( Site 2306)","Seville","Andalusia","41013","Spain",[670],{"name":131,"role":132,"phone":671},"+34955013068",{"lat":673,"lon":674},37.38283,-5.97317,{"facility":676,"status":8,"city":677,"state":678,"zip":679,"country":668,"contacts":680,"geoPoint":683},"Institut Català d'Oncologia - L'Hospitalet ( Site 2305)","L'Hospitalet de Llobregat","Barcelona","08908",[681],{"name":131,"role":132,"phone":682},"+34932607744",{"lat":684,"lon":685},41.35967,2.10028,{"facility":687,"status":8,"city":688,"state":689,"zip":690,"country":668,"contacts":691,"geoPoint":694},"HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)","Madrid","Madrid, Comunidad de","28007",[692],{"name":131,"role":132,"phone":693},"+34914269393",{"lat":695,"lon":696},40.4165,-3.70256,{"facility":698,"status":8,"city":678,"zip":699,"country":668,"contacts":700,"geoPoint":703},"Hospital Universitari Vall d'Hebron ( Site 2303)","08035",[701],{"name":131,"role":132,"phone":702},"+34934894350",{"lat":704,"lon":705},41.38879,2.15899,{"facility":707,"status":8,"city":708,"zip":709,"country":668,"contacts":710,"geoPoint":713},"Hospital Insular de Gran Canaria ( Site 2308)","Las Palmas","35016",[711],{"name":131,"role":132,"phone":712},"+34928441738",{"lat":714,"lon":715},28.58232,-16.16555,{"facility":717,"status":8,"city":688,"zip":718,"country":668,"contacts":719,"geoPoint":722},"Hospital Universitario 12 de Octubre ( Site 2300)","28041",[720],{"name":131,"role":132,"phone":721},"+34913908339",{"lat":695,"lon":696},{"facility":724,"status":8,"city":725,"zip":726,"country":668,"contacts":727,"geoPoint":730},"Fundación Instituto Valenciano de Oncología ( Site 2307)","Valencia","46009",[728],{"name":131,"role":132,"phone":729},"+34961114229",{"lat":731,"lon":732},39.47391,-0.37966,{"facility":734,"status":8,"city":735,"state":736,"zip":737,"country":738,"contacts":739},"Hacettepe Universite Hastaneleri ( Site 2500)","Sıhhiye","Ankara","06230","Turkey (Türkiye)",[740],{"name":131,"role":132,"phone":741},"+905439340493",{"facility":743,"status":8,"city":744,"zip":745,"country":738,"contacts":746,"geoPoint":749},"Adana Medical Park Seyhan Hastanesi ( Site 2505)","Adana","01140",[747],{"name":131,"role":132,"phone":748},"+905372688986",{"lat":750,"lon":751},36.98615,35.32531,{"facility":753,"status":8,"city":736,"zip":754,"country":738,"contacts":755,"geoPoint":758},"Ankara University Health Practice and Research Hospitals ( Site 2506)","06620",[756],{"name":131,"role":132,"phone":757},"+90 312 595 71 12",{"lat":759,"lon":760},39.91987,32.85427,{"facility":762,"status":8,"city":763,"zip":764,"country":738,"contacts":765,"geoPoint":768},"Trakya University Medical Faculty Hospital ( Site 2502)","Edirne","22030",[766],{"name":131,"role":132,"phone":767},"+9005378528123",{"lat":769,"lon":770},41.67719,26.55597,{"facility":772,"status":8,"city":773,"zip":774,"country":738,"contacts":775,"geoPoint":778},"Koc Universitesi Hastanesi ( Site 2501)","Istanbul","34010",[776],{"name":131,"role":132,"phone":777},"0090 850 250 8 250",{"lat":779,"lon":780},41.01384,28.94966,{"facility":782,"status":8,"city":783,"state":784,"zip":785,"country":786,"contacts":787,"geoPoint":790},"The Christie Hospital NHS Foundation Trust ( Site 2601)","Withington","Manchester","M20 4BX","United Kingdom",[788],{"name":131,"role":132,"phone":789},"0161 918 2546",{"lat":791,"lon":792},52.71667,-2.6,[794],{"name":795,"role":132,"phone":796,"email":797},"Toll Free Number","1-888-577-8839","Trialsites@msd.com",[799],{"name":800,"affiliation":13,"role":801},"Medical Director","STUDY_DIRECTOR",[],[804],{"label":805,"url":806},"Merck Clinical Trials Information","https:\u002F\u002Fwww.merckclinicaltrials.com\u002F",{"nct_id":4,"conditions":808,"biomarkers":810},[809],"Renal Cell Carcinoma",[],{"nct_id":4,"found":15,"summary":812,"prompt_version":822},{"design":813,"status":814,"heading":815,"summary":816,"follow_up":817,"word_count":818,"commitments":819,"compensation":820,"drugs_mentioned":821},"This interventional study plans to enroll 758 participants. It compares belzutifan plus zanzalintinib to belzutifan plus a placebo.","completed","A Study of Belzutifan and Zanzalintinib for Advanced Kidney Cancer","Researchers are studying new ways to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer. This study is testing if adding zanzalintinib to belzutifan, both targeted therapies, can better treat advanced RCC than belzutifan alone. Targeted therapies work by focusing on specific ways cancer cells grow and spread. You may be able to join if you have advanced RCC that has been confirmed by a biopsy and is measurable. The study aims to see if people who receive both belzutifan and zanzalintinib live longer overall and without their cancer getting worse. The current status of this study is unclear.","Participants will be followed for progression-free survival for up to approximately 30 months and for overall survival for up to approximately 50 months.",103,"Not specified in the trial record.","Not stated in the trial record.",[31,41],"v2"]